CA2232750A1 - Peptides et mimes de peptides inhibiteurs de l'action oncogenique de la p21 ras - Google Patents

Peptides et mimes de peptides inhibiteurs de l'action oncogenique de la p21 ras Download PDF

Info

Publication number
CA2232750A1
CA2232750A1 CA 2232750 CA2232750A CA2232750A1 CA 2232750 A1 CA2232750 A1 CA 2232750A1 CA 2232750 CA2232750 CA 2232750 CA 2232750 A CA2232750 A CA 2232750A CA 2232750 A1 CA2232750 A1 CA 2232750A1
Authority
CA
Canada
Prior art keywords
lys
val
asp
leu
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2232750
Other languages
English (en)
Inventor
Joseph J. Hlavka
Matthew R. Pincus
John Fowler Noble
Henry Baxter Abajian
Andrew S. Kende
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tetragenex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/531,525 external-priority patent/US5840683A/en
Application filed by Individual filed Critical Individual
Publication of CA2232750A1 publication Critical patent/CA2232750A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur des peptides, peptides cyclisés et mimes de peptides inhibiteurs de l'action oncogénique et/ou transformatrice de la protéine p21 <u>ras</u>, sur des préparations pharmaceutiques contenant au moins l'un des peptides, peptides cyclisés et mimes de peptides, inhibiteurs de la protéine p21 <u>ras</u>, et sur des procédés d'inhibition des processus oncogénique et/ou de transformation induits par la protéine p21 <u>ras</u> dans des cellules ou tissus de mammifères.
CA 2232750 1995-09-21 1996-09-20 Peptides et mimes de peptides inhibiteurs de l'action oncogenique de la p21 ras Abandoned CA2232750A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US409195P 1995-09-21 1995-09-21
US08/531,525 US5840683A (en) 1995-09-21 1995-09-21 Peptides inhibiting the oncogenic action of p21 ras
US60/004,091 1995-09-21
US08/531,525 1995-09-21

Publications (1)

Publication Number Publication Date
CA2232750A1 true CA2232750A1 (fr) 1997-03-27

Family

ID=26672587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2232750 Abandoned CA2232750A1 (fr) 1995-09-21 1996-09-20 Peptides et mimes de peptides inhibiteurs de l'action oncogenique de la p21 ras

Country Status (3)

Country Link
AU (1) AU7366896A (fr)
CA (1) CA2232750A1 (fr)
WO (1) WO1997010836A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022326A (en) * 1998-10-30 2000-02-08 Lifepoint, Inc. Device and method for automatic collection of whole saliva
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2838741B1 (fr) 2002-04-19 2006-01-27 Inst Nat Sante Rech Med Derives de sterols, leur procede de preparation et medicaments les comportant
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
US9328142B2 (en) * 2011-05-25 2016-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lipopeptide inhibitors of RAS oncoproteins
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
CA2903275A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs peptidiques permeables aux cellules de la voie de transduction du signal jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies
CN114409737B (zh) * 2022-02-24 2023-04-25 南阳师范学院 一种新型抗肿瘤肽及其应用

Also Published As

Publication number Publication date
WO1997010836A1 (fr) 1997-03-27
AU7366896A (en) 1997-04-09

Similar Documents

Publication Publication Date Title
CA2232750A1 (fr) Peptides et mimes de peptides inhibiteurs de l&#39;action oncogenique de la p21 ras
AU2008260326B2 (en) Cyclic peptide CXCR4 antagonists
AU746461B2 (en) Peptide parathyroid hormone analogs
JP7179241B1 (ja) 環状ペプチド化合物の医薬用途
CN117279933A (zh) 相对于hras和nras具有选择性kras抑制作用的环状化合物
US20020183249A1 (en) Method of identifying inhibitors of CDC25
US9982015B2 (en) Cyclin based inhibitors of CDK2 and CDK4
US5910478A (en) Peptidomimetics inhibiting the oncogenic action of p21 ras
CN105524139B (zh) 高活性的肿瘤抑制剂及其制法和应用
AU6382096A (en) Peptides and compounds that bind to the il-1 receptor
US20130289240A1 (en) Cyclin Based Inhibitors of CDK2 and CDK4
US20090131306A1 (en) Chemically modified cyclic peptides containing cell adhesion recognition (car) sequences and uses therefor
AU4236393A (en) Peptides and compounds that bind to elam-1
TW200410986A (en) Pharamaceutical comiposition comprising cyclic somatostatin analogs II
Jeremic et al. Synthesis of cyclohexapeptides containing Pro and Aib residues
US5840683A (en) Peptides inhibiting the oncogenic action of p21 ras
AU7077400A (en) Method of identifying inhibitors of cdc25
AU2007233105B2 (en) Amino acid surrogates for peptidic constructs
US10167326B2 (en) Alpha-fetoprotein “ring and tail” peptides
Frączak et al. The Biological Consequences of Replacing d‐Ala in Biphalin with Amphiphilic α‐Alkylserines
WO2002070680A1 (fr) Procede d&#39;identification d&#39;inhibiteurs de cdc25
CZ9904022A3 (cs) Peptidové analogy parathyroidálního hormonu

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead